- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03846128
Impact of Sunitinib Bioavailability on Toxicity and Treatment Efficacy in Patients Treated for Metastatic Renal Cancer (BIOSUNTOX)
July 22, 2019 updated by: University Hospital, Rouen
Patients treated on the first line of Sunitinib-targeted therapy for metastatic kidney cancer.
Collection of additional blood tubes during routine blood tests for patient follow-up, to evaluate the plasma concentration of Sunitinib and its active metabolite desethyl-Sunitinib (DES)
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
64
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patients treated on the first line of Sunitinib-targeted therapy for metastatic kidney cancer
Description
Inclusion Criteria:
- Patient at least 18 years old
- Patient who read and understood the newsletter and signed the consent form
- Renal cell carcinoma histologically proven stage IV
- Metastatic stage proven on CT, synchronous or metachronous examination
- Patient operated on or not from the primary tumor
- Eligible for first-line systemic therapy with Sunitinib-targeted therapy for oncology urology
- Affiliation to a social security scheme
- Effective contraception (as defined by the WHO) for at least 3 months at the inclusion visit, during treatment and for 1 month after the end of the research (negative pregnancy test)
- Postmenopausal woman: confirmatory diagnosis (amenorrhea not clinically induced for more than 12 months at inclusion visit)
- General condition WHO 0 to 2
- Life expectancy estimated at more than 6 months at baseline
Exclusion Criteria:
- Non-metastatic disease
- Other cancer proven histologically, or in complete remission for less than 2 years
- Contraindication to SUTENT 50 mg hard capsules: Hypersensitivity to the active substance or to any of the excipients
- History of immunotherapy treatment for kidney cancer, previous treatment with targeted therapies for the same or previous cancer
- Pregnant or lactating woman or wishing to breastfeed within 6 months after the last treatment or no known contraception,
- Person deprived of liberty by an administrative or judicial decision or person placed under the protection of justice / sub-guardianship or curatorship
- Patient currently involved in an interventional trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
hazard ratio of a severe toxicity, grade 3-4 clinical and / or biologicalas according to the plasma concentration of Sunitinib
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
hazard ratio of a severe toxicity, grade 3-4 clinical and / or biologicalas according to the plasma concentration of Sunitinib
|
At the end of Cycle 1 (each cycle is 28 days)
|
hazard ratio of a severe toxicity, grade 3-4 clinical and / or biologicalas according to the plasma concentration of Sunitinib
Time Frame: At the end of Cycle 2 (each cycle is 28 days)
|
hazard ratio of a severe toxicity, grade 3-4 clinical and / or biologicalas according to the plasma concentration of Sunitinib
|
At the end of Cycle 2 (each cycle is 28 days)
|
hazard ratio of a severe toxicity, grade 3-4 clinical and / or biologicalas according to the plasma concentration of Sunitinib
Time Frame: At the end of Cycle 3 (each cycle is 28 days)
|
hazard ratio of a severe toxicity, grade 3-4 clinical and / or biologicalas according to the plasma concentration of Sunitinib
|
At the end of Cycle 3 (each cycle is 28 days)
|
hazard ratio of a severe toxicity, grade 3-4 clinical and / or biologicalas according to the plasma concentration of Sunitinib
Time Frame: At the end of Cycle 4 (each cycle is 28 days)
|
hazard ratio of a severe toxicity, grade 3-4 clinical and / or biologicalas according to the plasma concentration of Sunitinib
|
At the end of Cycle 4 (each cycle is 28 days)
|
hazard ratio of a severe toxicity, grade 3-4 clinical and / or biologicalas according to the plasma concentration of Sunitinib
Time Frame: At the end of Cycle 5 (each cycle is 28 days)
|
hazard ratio of a severe toxicity, grade 3-4 clinical and / or biologicalas according to the plasma concentration of Sunitinib
|
At the end of Cycle 5 (each cycle is 28 days)
|
hazard ratio of a severe toxicity, grade 3-4 clinical and / or biologicalas according to the plasma concentration of Sunitinib
Time Frame: At the end of Cycle 6 (each cycle is 28 days)
|
hazard ratio of a severe toxicity, grade 3-4 clinical and / or biologicalas according to the plasma concentration of Sunitinib
|
At the end of Cycle 6 (each cycle is 28 days)
|
hazard ratio of a severe toxicity, grade 3-4 clinical and / or biological according to the plasma concentration of desethyl-Sunitinib
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
hazard ratio of a severe toxicity, grade 3-4 clinical and / or biological according to the plasma concentration of desethyl-Sunitinib
|
At the end of Cycle 1 (each cycle is 28 days)
|
hazard ratio of a severe toxicity, grade 3-4 clinical and / or biological according to the plasma concentration of desethyl-Sunitinib
Time Frame: At the end of Cycle 2 (each cycle is 28 days)
|
hazard ratio of a severe toxicity, grade 3-4 clinical and / or biological according to the plasma concentration of desethyl-Sunitinib
|
At the end of Cycle 2 (each cycle is 28 days)
|
hazard ratio of a severe toxicity, grade 3-4 clinical and / or biological according to the plasma concentration of desethyl-Sunitinib
Time Frame: At the end of Cycle 3 (each cycle is 28 days)
|
hazard ratio of a severe toxicity, grade 3-4 clinical and / or biological according to the plasma concentration of desethyl-Sunitinib
|
At the end of Cycle 3 (each cycle is 28 days)
|
hazard ratio of a severe toxicity, grade 3-4 clinical and / or biological according to the plasma concentration of desethyl-Sunitinib
Time Frame: At the end of Cycle 4 (each cycle is 28 days)
|
hazard ratio of a severe toxicity, grade 3-4 clinical and / or biological according to the plasma concentration of desethyl-Sunitinib
|
At the end of Cycle 4 (each cycle is 28 days)
|
hazard ratio of a severe toxicity, grade 3-4 clinical and / or biological according to the plasma concentration of desethyl-Sunitinib
Time Frame: At the end of Cycle 5 (each cycle is 28 days)
|
hazard ratio of a severe toxicity, grade 3-4 clinical and / or biological according to the plasma concentration of desethyl-Sunitinib
|
At the end of Cycle 5 (each cycle is 28 days)
|
hazard ratio of a severe toxicity, grade 3-4 clinical and / or biological according to the plasma concentration of desethyl-Sunitinib
Time Frame: At the end of Cycle 6 (each cycle is 28 days)
|
hazard ratio of a severe toxicity, grade 3-4 clinical and / or biological according to the plasma concentration of desethyl-Sunitinib
|
At the end of Cycle 6 (each cycle is 28 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
plasma desethyl-Sunitinib (DES) concentration
Time Frame: Cycle1 Day14 (each cycle is 28 days)
|
influence of plasma DES concentration on patients survival
|
Cycle1 Day14 (each cycle is 28 days)
|
plasma Sunitinib concentration
Time Frame: Cycle1 Day14 (each cycle is 28 days)
|
influence of plasma Sunitinib concentration on patients survival
|
Cycle1 Day14 (each cycle is 28 days)
|
plasma Sunitinib concentration
Time Frame: Cycle1 Day28 (each cycle is 28 days)
|
influence of plasma Sunitinib concentration on patients survivall
|
Cycle1 Day28 (each cycle is 28 days)
|
plasma DES concentration
Time Frame: Cycle1 Day28 (each cycle is 28 days)
|
influence of plasma Sunitinib concentration on patients survival
|
Cycle1 Day28 (each cycle is 28 days)
|
plasma Sunitinib concentration
Time Frame: Cycle2 Day28(each cycle is 28 days)
|
influence of plasma Sunitinib concentration on patients survival
|
Cycle2 Day28(each cycle is 28 days)
|
plasma DES concentration
Time Frame: Cycle2 Day28 (each cycle is 28 days)
|
influence of plasma DES concentration on patients survival
|
Cycle2 Day28 (each cycle is 28 days)
|
plasma Sunitinib concentration
Time Frame: Cycle3 Day28 (each cycle is 28 days)
|
influence of plasma Sunitinib concentration on patients survival
|
Cycle3 Day28 (each cycle is 28 days)
|
plasma DES concentration
Time Frame: Cycle3 Day28 (each cycle is 28 days)
|
Evaluate the influence of plasma DES concentration on patients survival
|
Cycle3 Day28 (each cycle is 28 days)
|
plasma Sunitinib concentration
Time Frame: Cycle6 Day28 (each cycle is 28 days)
|
influence of plasma Sunitinib concentration on patients survival
|
Cycle6 Day28 (each cycle is 28 days)
|
plasma DES concentration
Time Frame: Cycle6 Day28 (each cycle is 28 days)
|
influence of plasma DES concentration on patients survival
|
Cycle6 Day28 (each cycle is 28 days)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
August 1, 2019
Primary Completion (ANTICIPATED)
May 1, 2024
Study Completion (ANTICIPATED)
May 1, 2024
Study Registration Dates
First Submitted
January 31, 2019
First Submitted That Met QC Criteria
February 15, 2019
First Posted (ACTUAL)
February 19, 2019
Study Record Updates
Last Update Posted (ACTUAL)
July 23, 2019
Last Update Submitted That Met QC Criteria
July 22, 2019
Last Verified
July 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017/181/HP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Kidney Cancer
-
Gustave Roussy, Cancer Campus, Grand ParisCompletedGIST Metastatic Cancer | Breast Metastatic Cancer | Kidney Metastatic Cancer | Colon Metastatic Cancer | Rectal Metastatic CancerFrance
-
Western Regional Medical CenterTerminatedKidney Cancer Metastatic | Renal Cell Cancer MetastaticUnited States
-
Virginia Commonwealth UniversityUnited States Department of DefenseRecruitingBrain Cancer | Brain Tumor | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Melanoma | Brain Metastases | Metastatic Colon Cancer | Metastatic Kidney CancerUnited States
-
Tampere University HospitalUniversity of Turku; University of Helsinki; Tampere University; Aalto UniversityRecruitingKidney Cancer | Breast Cancer | Metastatic Renal Cell Carcinoma | Ovarian Cancer | Prostate Cancer | Metastatic Breast Cancer | Metastatic Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Ovarian Cancer | Metastatic Renal Cancer | Metastatic Kidney Cancer | Metastatic Ovary CancerFinland
-
Centre Hospitalier Universitaire de Saint EtienneTerminatedMetastatic Renal Cell Carcinoma | Metastatic Kidney CancerFrance
-
NewLink Genetics CorporationCompletedMetastatic Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Metastatic Kidney Cancer | Refractory Renal Cell Carcinoma | Metastatic Clear-cell Renal CancerUnited States
-
University of Texas Southwestern Medical CenterCompletedKidney Cancer | Kidney Cancer Metastatic | Kidney Cancer, Stage IVUnited States
-
Centre Hospitalier Universitaire de BesanconTerminated
-
Duke UniversityCompletedMetastatic Renal Cell Carcinoma | Metastatic Urothelial Carcinoma | Metastatic Castration-resistant Prostate Cancer (mCRPC)United States
-
National Cancer Institute (NCI)CompletedMetastatic Melanoma | Metastatic Kidney CancerUnited States
Clinical Trials on blood sample
-
Medical University of WarsawCompletedArthroplasty | Platelet Aggregation | Methylmethacrylate EmbolismPoland
-
Memorial Sloan Kettering Cancer CenterActive, not recruiting
-
Meir Medical CenterCompleted
-
First Affiliated Hospital of Zhejiang UniversityRecruitingComplication | Hematologic Malignancy | Hematopoietic Stem Cell Transplantation | Chronic Graft-versus-host-diseaseChina
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceRecruitingImmune Thrombocytopenia | Autoimmune Hemolytic Anemia | Autoimmune NeutropeniaFrance
-
University Hospital, ToursCompletedMetastatic Prostate Cancer | Circulating Tumor DNAFrance
-
University Hospital, BordeauxActive, not recruitingSystemic Lupus Erythematosus | Systemic SclerodermaFrance
-
University Hospital, BordeauxCompletedRenal Function Disorder | Chronic Renal Diseases
-
University Hospital, ToursNot yet recruitingRenal Transplant | ConversionFrance